No evidence of benefit from citalopram in treatment of bipolar depression | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

No evidence of benefit from citalopram in treatment of bipolar depression

Publication year - 2021

Publication title -

the brown university psychopharmacology update

Language(s) - English

Resource type - Journals

eISSN - 1556-7532

pISSN - 1068-5308

DOI - 10.1002/pu.30714

Subject(s) - citalopram , depression (economics) , serotonin reuptake inhibitor , medicine , placebo , bipolar disorder , psychiatry , clinical trial , anxiety , antidepressant , mood , alternative medicine , economics , macroeconomics , pathology

Patients receiving citalopram as adjunctive treatment for bipolar depression experienced no significant improvement relative to placebo in a clinical trial that measured both acute and maintenance treatment response. This was the first study to evaluate the efficacy of a serotonin reuptake inhibitor (SRI) for the maintenance treatment of bipolar depression. Results were published online Jan. 12 in the Journal of Clinical Psychiatry .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research